Table 4B. Biomarker profile of enrolled lung cancer patients.
| n (%) | EGFR-positivea | ALK-positive | KRAS-positive | BRAF-positive | ROS1-positive | Positive for at least one biomarkerb |
|---|---|---|---|---|---|---|
| Small cell carcinoma (N = 67) | 26 (1.4) | 4 (0.3) | 0 (0) | 0 (0) | 0 (0) | 30 (1.5) |
|
Non-small cell carcinoma (N = 1,982) |
804 (44.1) | 121 (8.2) | 10 (9.1) | 3 (1.4) | 27 (4.3) | 940 (45.9) |
|
Adenocarcinoma (N = 1,507) |
729 (40.0) | 103 (7.0) | 9 (8.2) | 3 (1.4) | 23 (3.7) | 846 (41.3) |
| Squamous cell carcinoma (N = 325) | 36 (2.0) | 8 (0.5) | 0 (0) | 0 (0) | 0 (0) | 44 (2.2) |
| Adenosquamous carcinoma (N = 19) | 8 (0.4) | 1 (0.1) | 0 (0) | 0 (0) | 0 (0) | 9 (0.4) |
|
Large cell carcinoma (N = 9) |
2 (0.1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (0.1) |
|
Others (N = 121) |
29 (1.6) | 9 (0.6) | 1 (0.9) | 0 (0) | 4 (0.6) | 39 (1.9) |
a%=n/total number of specific biomarker test.
bPatients could be positive for more than one biomarker, total number of patients who were analyzed n = 2,049.